<DOC>
	<DOCNO>NCT02531321</DOCNO>
	<brief_summary>The project two-arm prospective cohort pharmacokinetic study compare levonorgestrel ethinyl estradiol pharmacokinetics HIV-positive woman take antiretroviral regimen include ritonavir woman take regimen know interact combined oral contraceptive . In addition , prevalence ovulation measure group . Participants take combine oral contraceptive contain levonorgestrel ethinyl estradiol 21 day , undergo twice-weekly serum progesterone . On final day , complete pharmacokinetic study . The investigator hypothesize levonorgestrel level , measure area-under-the-curve 0 72 hour , increase woman ritonavir , ethinyl estradiol level decrease ovulation , define serum progesterone least 3 ng/mL , unchanged . This study first evaluate effect ritonavir pharmacokinetics combine oral contraceptive contain progestin levonorgestrel . In addition , previous study rigorously assess ovulation woman take protease inhibitor combine oral contraceptive . As result , study provide new information correlate pharmacokinetic change effect ovulation .</brief_summary>
	<brief_title>Protease Inhibitors Combined Oral Contraceptive Pharmacokinetics Pharmacodynamics</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>HIV positive Female Age 1845 Using follow medication regimen : ARV medication , entry inhibitor , nucleoside reverse transcriptase inhibitor ( NRTIs ) , integrase inhibitor , CCR5 agonists . Acceptable NRTI combination include zidovudine ( ZDV ) , lamivudine ( 3TC ) , emtricitabine ( FTC ) , didanosine ( ddl ) , stavudine ( d4T ) , abacavir ( ABC ) , tenofovir disoproxil fumarate ( TDF ) Ovulatory ( midluteal progesterone &gt; 3ng/dL ) Not plan conceive study period Willing abstain grapefruit product If take ritonavir , willing use alternate nonhormonal contraception BMI &lt; = 40 Able consent English Spanish No change medication regimen least 21 day prior study entry plan change study period CD4 &gt; =200 , and/or consider profoundly immuncompromised primary HIV provider Using combination ZDV d4T Platelets &lt; 50,000 AST ALT &gt; twice upper limit normal Bilirubin &gt; twice upper limit normal Use CYP3A4 induce inhibit medication Pregnant breastfeed last 30 day Use DepoProvera last 180 day Use hormonal contraception last 30 day Undiagnosed vaginal bleeding invasive cancer reproductive tract &gt; 50 % change tobacco use last month Initiation titration methadone therapy last month Uncontrolled thyroid disease Contraindication estrogen use Inability comply study protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>